Physician profile
Thomas G Capelli
NPI 1487698155
$4,866.26
in general payments reported to CMS, 2019-2025
28 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $617 · 2021: $773 · 2022: $691 · 2023: $652 · 2024: $686 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.10 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $607.17 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $534.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $495.05 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.52 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $276.95 | 2020-2024 | Trintellix |
| Lundbeck LLC | $234.03 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $151.12 | 2020-2022 | |
| Insmed, INC. | $138.48 | 2019 | |
| Allergan, INC. | $121.70 | 2020 | |
| Exact Sciences Corporation | $113.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $106.72 | 2022 | |
| Novo Nordisk INC | $106.52 | 2022-2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $96.02 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $81.25 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.87 | 2019-2025 | Otezla, Repatha |
| Dexcom, INC. | $48.05 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $43.00 | 2024-2025 | Mounjaro, Zepbound |
| Ucb, INC. | $37.19 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.46 | 2021 | |
| Nevro Corp. | $29.74 | 2019 | |
| Boston Scientific Corporation | $26.24 | 2025 | Watchman Access System |
| Ars Pharmaceuticals Operations, INC. | $23.25 | 2025 | Neffy |
| Otsuka America Pharmaceutical, INC. | $21.90 | 2024 | Rexulti |
| Ibsa Pharma INC. | $20.46 | 2024 | Flector, Licart, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $17.91 | 2020 | |
| Astellas Pharma US INC | $17.43 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.84 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Capelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.